Nuvation Bio
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 51
- Market Cap
- $767.6M
- Introduction
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was fou...
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 466
- Registration Number
- NCT06334432
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Fred Hutchinson, Seattle, Washington, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
Study the Effect of Omeprazole on AB-106 Pharmacokinetics
- Conditions
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05609929
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05357911
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK
- Conditions
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05357820
- Locations
- 🇨🇳
Xuanwu Hospital of Capital Medical University, Beijing, China
Safusidenib Phase 2 Study in IDH1 Mutant Glioma
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05303519
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 657
- Registration Number
- NCT05252390
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸St. Vincent-Frontier Cancer Center, Billings, Montana, United States
🇺🇸Morristown Medical Center, Morristown, New Jersey, United States
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Nuvation Bio Inc.
- Registration Number
- NCT05191017
- Locations
- 🇺🇸
Pennsylvania Cancer Specialists and Research Institute, Gettysburg, Pennsylvania, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸NEXT Virginia, Fairfax, Virginia, United States
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Nuvation Bio Inc.
- Registration Number
- NCT05191004
- Locations
- 🇺🇸
Pennsylvania Cancer Specialists and Research Institute, Gettysburg, Pennsylvania, United States
🇺🇸Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Compassionate Cancer Care Research Inc., Fountain Valley, California, United States
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT04919811
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸SCRI - Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Renovatio Clinical, Dallas, Texas, United States
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT04541225
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
🇺🇸Texas Oncology P.A. Austin, Austin, Texas, United States